What is Aura Biosciences Cash-to-Debt?
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Aura Biosciences's cash to debt ratio for the quarter that ended in Mar. 2024 was 10.50.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Aura Biosciences could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.
The historical rank and industry rank for Aura Biosciences's Cash-to-Debt or its related term are showing as below:
AURA'
s Cash-to-Debt Range Over the Past 10 Years
Min: 5.29 Med: 42.31 Max: No Debt
Current: 10.5
During the past 5 years, Aura Biosciences's highest Cash to Debt Ratio was No Debt. The lowest was 5.29. And the median was 42.31.
Aura Biosciences Cash-to-Debt Historical Data
The historical data trend for Aura Biosciences's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Aura Biosciences Cash-to-Debt Chart
|
Aura Biosciences Annual Data
|
|
Trend |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Cash-to-Debt |
|
662.22 |
No Debt |
152.89 |
9.05 |
11.56 |
|
Aura Biosciences Quarterly Data
|
|
Dec19 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
| Cash-to-Debt |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
8.41 |
7.94 |
7.38 |
11.56 |
10.50 |
Competitive Comparison of Aura Biosciences's Cash-to-Debt
For the Biotechnology subindustry, Aura Biosciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aura Biosciences's Cash-to-Debt Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aura Biosciences's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Aura Biosciences's Cash-to-Debt falls into.
Aura Biosciences Cash-to-Debt Calculation
This is the ratio of a company's
Cash, Cash Equivalents, Marketable Securities
to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.
Aura Biosciences's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
Aura Biosciences's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aura Biosciences (Aura Biosciences) Business Description
Traded in Other Exchanges
N/A
Address
85 Bolton Street, Cambridge, MA, USA, 02140
Aura Biosciences Inc is a clinical-stage oncology company developing a novel technology platform based on virus-like drug conjugates to target and destroy cancer cells selectively while activating the immune system to create long-lasting anti-tumor immunity.
Executives
| Matrix Capital Management Company, Lp |
10 percent owner |
1000 WINTER STREET, C/O MATRIX CAPITAL MANAGEMENT, WALTHAM MA 02451 |
| David Michael Johnson |
director |
C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018 |
| Julie B Feder |
officer: Chief Financial Officer |
C/O VERASTEM, INC., 117 KENDRICK STREET, SUITE 500, NEEDHAM MA 02494 |
| De Los Pinos Elisabet |
director, officer: Chief Executive Officer |
C/O AURA BIOSCIENCES, INC., 85 BOLTON STREET, CAMBRIDGE MA 02140 |
| Janet Jill Hopkins |
officer: See Remarks |
C/O AURA BIOSCIENCES, INC., 80 GUEST STREET, BOSTON MA 01235 |
| Cadmus Rich |
officer: See Remarks |
C/O AURA BIOSCIENCES, INC., 85 BOLTON STREET, CAMBRIDGE MA 02140 |
| Rosch Mark De |
officer: Chief Operating Officer |
C/O AURA BIOSCIENCES, INC., 85 BOLTON STREET, CAMBRIDGE MA 02140 |
| Medicxi Ventures Management (jersey) Ltd |
10 percent owner |
C/O INTERTRUST FUND SERVICES (JERSEY), 44 ESPLANADE, ST. HELIER Y9 JE4 9WG |
| Medicxi Growth I Lp |
10 percent owner |
C/O ELIAN FUND SERVICES (JERSEY) LIMITED, 44 ESPLANADE, ST HELIER Y9 JE4 9WG |
| Giovanni Mariggi |
director |
C/O AURA BIOSCIENCES, INC., 85 BOLTON STREET, CAMBRIDGE MA 02140 |
| Medicxi Growth I Gp Ltd |
10 percent owner |
C/O INTERTRUST FUND SERVICES (JERSEY), 44 ESPLANADE, ST. HELIER Y9 JE4 9WG |
| Medicxi Growth Co-invest I Lp |
10 percent owner |
C/O INTERTRUST FUND SERVICES (JERSEY), 44 ESPLANADE, ST. HELIER Y9 JE4 9WG |
| David E. Goel |
10 percent owner |
C/O MATRIX CAPITAL MANAGEMENT CO., LP, 1000 WINTER STREET, SUITE 4500, WALTHAM MA 02451 |
| Karan S. Takhar |
director |
C/O ZENTALIS PHARMACEUTICALS,INC., 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018 |
| Antony C. Mattessich |
director |
C/O OCULAR THERAPEUTIX, INC., 34 CROSBY DR., SUITE 105, BEDFORD MA 01730 |
Aura Biosciences (Aura Biosciences) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AURA has been successfully added to your